Sunitinib in patients with imatinib-resistant gastrointestinal stromal tumor : (Record no. 81170)

000 -LEADER
fixed length control field 03196pab a2200373 454500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 161010b2015 xxu||||| |||| 00| 0 eng d
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Sahu A
245 ## - TITLE STATEMENT
Title Sunitinib in patients with imatinib-resistant gastrointestinal stromal tumor :
Remainder of title A single center experiencep-190 chronic myelogenous leukemia presenting as extramedullary blast crisis
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Place of publication, distribution, etc. Mumbai
Name of publisher, distributor, etc. Medknow Publications
Date of publication, distribution, etc. 2015
300 ## - PHYSICAL DESCRIPTION
Extent 320-323
490 ## - SERIES STATEMENT
Series statement Vol. 3 ,no. 52
520 ## - SUMMARY, ETC.
Summary, etc. AIM: The outcome of patients with advanced gastrointestinal stromal tumor (GIST) has improved with the use of imatinib. Despite high response rates with this drug resistance eventually develops in nearly all patients. We present an analysis of prospectively collected data on sunitinib efficacy and safety in patients with imatinib-resistant GIST. SUBJECTS AND METHODS: Between November 2006 and October 2007, patients with GIST were accrued in an approved sunitinib patient access protocol. Key eligibility criteria included tumor resistance to imatinib and/or patient intolerance to this drug. Patients received sunitinib at a starting dose of 50 mg once daily for 4 weeks in a 6 week cycle, with standardized dose modification titrated to toxicity. Patients were continued on sunitinib until disease progression or unacceptable toxicity. The endpoints were safety, overall survival (OS) and objective response rate (ORR). RESULTS: Fifteen patients, all of whom had imatinib resistance and none intolerance, with median age of 48 (26-69) years, were treated on the protocol. The most common sites of primary disease were small intestine (40%), stomach (26.7%) and retroperitoneal (26.7%). A median of 10 (1-47) cycles of sunitinib were delivered, 9 (60%) patients required dose reductions due to toxicity whereas dose delay of > 2 weeks was required in only one (6.7%) patient. There were no toxicity-related drug discontinuations. Hypothyroidism (n = 4; 26.7%) and hand-foot syndrome (n = 3; 20%) were the most common toxicities. There were no complete and 4 (26.7%) partial responses while prolonged disease stability was seen in 8 (53.3%) patients. At a median follow-up of 81 months in surviving patients, the median progression-free and overall survivals were 15.5 and 18.7 months, respectively. CONCLUSIONS: Sunitinib appears to be an effective and well-tolerated treatment for Indian patients with imatinib-resistant GIST with outcomes similar to that reported previously. Adverse effects can be reasonably well managed using a dose modification strategy.
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Location of event Gastrointestinal stromal tumor
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Location of event Imatinib-resistant
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Location of event Sunitinib
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Gupta S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Kembhavi Y
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Bajpai J
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Gulia S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Goyal M
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Ramadwar M
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Shrikhande S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Ghosh J
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Jain P
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Godbole S
773 ## - HOST ITEM ENTRY
Main entry heading Indian Journal of Cancer
Place, publisher, and date of publication Mumbai : Medknow Publications
International Standard Serial Number 1998-4774
Related parts Vol.52, no.3, p.320-323
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://10.3.0.2/mm01/Articles/AR17711.pdf
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
h TMH
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
b TMC
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
a Anaesthesiology
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
c 26905126
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
f National
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
e journalArticle
Holdings
Withdrawn status Lost status Damaged status Not for loan Permanent Location Current Location Date acquired Barcode Date last seen Price effective from Koha item type
        Tata Memorial Hospital Tata Memorial Hospital 2017-01-19 AR17711 2017-01-19 2017-01-19 Articles

Powered by Koha